Laborie Medical Technologies Inc. continued a string of recent deals with an agreement to acquire Urotronic Inc. for $255 million cash up front with an additional $345 million in payments contingent on meeting specified commercial and reimbursement milestones. Laborie already held a minority interest in the manufacturer of the Optilume drug-coated balloon technology for treatment of urethral strictures and benign prostatic hyperplasia (BPH).
Related Keywords
, Laborie Medical Technologies Inc , Urotronic Inc , Laborie Medical Technologies , Urotronics Inc , Novonate Inc , Gi Supply Inc , Eclipse , Lifebubble , Optilume , Urethral Stricture , Gastrointestinal Stricture , Benign Prostatic Hyperplasia ,
comparemela.com © 2020. All Rights Reserved.